Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease

被引:179
作者
Lohr, Jens
Knoechel, Birgit
Wang, Jing Jing
Villarino, Alejandro V.
Abbas, Abul K. [1 ]
机构
[1] Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA
关键词
D O I
10.1084/jem.20061341
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To explore the interactions between regulatory T cells and pathogenic effector cytokines, we have developed a model of a T cell-mediated systemic autoimmune disorder resembling graft-versus-host disease. The cytokine responsible for tissue inflammation in this disorder is interleukin (IL)-17, whereas interferon (IFN)-gamma produced by Th1 cells has a protective effect in this setting. Because of the interest in potential therapeutic approaches utilizing transfer of regulatory T cells and inhibition of the IL-2 pathway, we have explored the roles of these in the systemic disease. We demonstrate that the production of IL-17 and tissue infiltration by IL-17-producing cells occur and are even enhanced in the absence of IL-2. Regulatory T cells favor IL-17 production but prevent the disease when administered early in the course by suppressing expansion of T cells. Thus, the pathogenic or protective effects of cytokines and the therapeutic capacity of regulatory T cells are crucially dependent on the timing and the nature of the disease.
引用
收藏
页码:2785 / 2791
页数:7
相关论文
共 29 条
[1]   Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ [J].
Anderson, BE ;
McNiff, JM ;
Jain, D ;
Blazar, BR ;
Shlomchik, WD ;
Shlomchik, MJ .
BLOOD, 2005, 105 (05) :2227-2234
[2]   Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells [J].
Bettelli, E ;
Carrier, YJ ;
Gao, WD ;
Korn, T ;
Strom, TB ;
Oukka, M ;
Weiner, HL ;
Kuchroo, VK .
NATURE, 2006, 441 (7090) :235-238
[3]  
COUSENS LP, 1995, J IMMUNOL, V155, P5690
[4]   TGF-β, a 'double agent' in the immune pathology war [J].
Cua, DJ ;
Kastelein, RA .
NATURE IMMUNOLOGY, 2006, 7 (06) :557-559
[5]   Anti-TNF therapy: Where have we got to in 2005? [J].
Feldmann, M ;
Brennan, FM ;
Foxwell, BMJ ;
Taylor, PC ;
Williams, RO ;
Maini, RN .
JOURNAL OF AUTOIMMUNITY, 2005, 25 :26-28
[6]   Design of effective immunotherapy for human autoimmunity [J].
Feldmann, M ;
Steinman, L .
NATURE, 2005, 435 (7042) :612-619
[7]   Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages [J].
Harrington, LE ;
Hatton, RD ;
Mangan, PR ;
Turner, H ;
Murphy, TL ;
Murphy, KM ;
Weaver, CT .
NATURE IMMUNOLOGY, 2005, 6 (11) :1123-1132
[8]   The potential of human regulatory T cells generated ex vivo as a treatment for lupus and other chronic inflammatory diseases [J].
Horwitz, DA ;
Gray, JD ;
Zheng, SG .
ARTHRITIS RESEARCH, 2002, 4 (04) :241-246
[9]   Sequential development of interleukin 2 dependent effector and regulatory T cells in response to endogenous systemic antigen [J].
Knoechel, B ;
Lohr, J ;
Kahn, E ;
Bluestone, JA ;
Abbas, AK .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (10) :1375-1386
[10]   Functional and molecular comparison of anergic and regulatory T lymphocytes [J].
Knoechel, Birgit ;
Lohr, Jens ;
Zhu, Shirley ;
Wong, Lisa ;
Hu, Donglei ;
Ausubel, Lara ;
Abbas, Abul K. .
JOURNAL OF IMMUNOLOGY, 2006, 176 (11) :6473-6483